Bullish
$PRVB considering the cost of T1D to health insurance companies and governments in the USA, Canada and around the world, Teplizumab’s breakthrough may well drive a policy shift - requiring Screening for T1D in, first the at-risk populous, and then the general population. This will permit dramatic reduction in treatment costs, an explosive use of Teplizumab - and a healthier world. Win-win-win. And of you are long (as I am)....add one more win to that pile! as @Jwa68 so famously puts it...”stay the course”
  • 7
  • 1